Free Gastroenterology CME

  • FREE

    Healio Free Gastroenterology CME

    Find out what over 50,000 of your colleagues already know. Earn credits faster and easier with Healio CME.

    See full details chevron_right
    • Cost: Free
    • Credit hours: Varies
  • FREE

    ScientiaCME Gastroenterology

    This course contains two courses:

    Target Audience:

    Healthcare professionals specializing in colon and rectal surgery, family medicine, internal medicine, gastroenterology, oncology, pain management, palliative care, primary care, proctology, and other clinicians who treat patients suffering from gastrointestinal disorders.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 2.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Expiration of CME credit: Two years after release.
  • FREE

    CME: Metastatic colorectal cancer (mCRC) treatment: Therapeutic updates, best practices, and barriers to care

    Colorectal cancer (CRC) is the third-leading cause of cancer deaths in the U.S. While a majority of patients are diagnosed before their disease has metastasized, a fifth of patients have advanced disease at the time of diagnosis. Early detection and screening have been shown to significantly reduce CRC mortality, and screening is widely recommended for average-risk adults beginning at age 50 years, (as well as earlier for individuals at higher risk). Since the mid-1990s, the U.S. Preventive Services Task Force, American Cancer Society, and other groups have recommended several modalities for screening: fecal occult blood testing (FOBT), flexible sigmoidoscopy, colonoscopy, and barium enema. Recent years have seen the addition of newer screening technologies, including stool DNA, computed tomographic colonography, and capsule endoscopy.

    Target Audience:

    Healthcare professionals including: medical oncologists, primary care physicians, pathologists, gastroenterologists, and managed care medical care directors; physicians assistants, nurse practitioners, nurses, and pharmacists specializing in oncology; and other clinicians who are involved in providing diagnostic and therapeutic services for patients with CRC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 2/3/2021
    • Expiration of CME credit: 2/3/2023
  • FREE

    Ulcerative Colitis (UC): Optimizing Pharmacotherapeutic Management Strategies

    Inflammatory bowel disease (IBD) is a broad term that includes many different forms of inflammatory bowel conditions, the most common of which are ulcerative colitis (UC) and Crohn’s disease (CD), the former of which exclusively affects the colon and rectum. UC occurs more frequently than CD, with an incidence of 1.2 to 20.3 cases per 100,000 persons per year and a prevalence of 7.6 to 246.0 cases per 100,000 per year, as compared to 0.03 to 15.6 and 3.6 to 214.0 per 100,000 for CD. Risk factors include characteristics common in westernized environments and lifestyles, including smoking, diets high in fat and sugar, medication use, stress, and high socioeconomic status.

    Target Audience:

    HCPs specializing in: gastroenterology, internal medicine; nurse practitioners, physician assistants, and pharmacists who specialize in gastroenterology; and those who otherwise commonly care for or clinically encounter patients with UC.

    By the end of the session the participant will be able to:

    • Describe the burden of disease UC represents to patients.
    • Identify the present treatment options currently available for management of UC and apply them to patient cases using evidence-based medicine.
    • Identify new and emerging therapies for the treatment of UC.
    • Evaluate a treatment plan for a specific patient based on severity of UC to optimize safety, efficacy, and cost-efficacy, suggesting modifications for improvement.
    See full details chevron_right
    • Cost: Free
    • Credit hours: .75
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 07/22/2020
    • Expiration of CME credit: 07/22/2022
  • FREE

    The difficulty with (C.) difficile: guideline updates and optimal identification and treatment strategies

    Activity Description / Statement of Need:

    Clostridioides difficile (formerly known as Clostridium difficile) is a gram-positive obligate anaerobe that produces exotoxins in the gastrointestinal (GI) tract resulting in watery, loose stool, abdominal pain, and nausea. The U.S. incidence of Clostridioides difficile infection (CDI) is about half a million people, with 28% community-acquired, 37% healthcare-associated, and 36% associated with long-term care facilities. Additionally, CDI has incurred one billion dollars in costs to the U.S. healthcare system. Antibiotic exposure causes changes to the GI microflora and increases the risk of developing CDI, which is especially seen in carbapenems, third-/fourth- generation cephalosporins, clindamycin, and fluoroquinolone use. Other risk factors include acid suppressive therapy; age; prolonged hospitalizations or other recent healthcare exposure; recent tube feeding or GI surgery; and immunocompromised states, including recent chemotherapy.

    Target Audience:

    HCPs including: infectious diseases physicians, gastroenterologists, hospitalists, and intensivists; physician assistants, nurse practitioners, and pharmacists who practice in the aforementioned areas of specialty; and any other HCPs with an interest in or who clinically encounter patients with CDI. 

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 02/04/2022
    • Expiration of CME credit: 02/04/2024
  • FREE

    Closing the gap in the treatment of constipation-predominant irritable bowel syndrome (IBS-C): From recognition to treating the patient

    Activity Description / Statement of Need:

    In this online, self-learning activity:

    Irritable bowel syndrome (IBS) is among the most common disorders seen by primary care as well as gastroenterology specialty clinics. Patients with IBS usually present with chronic abdominal pain and altered bowel habit, in the absence of any other disease to cause these sorts of symptoms. The disorder is associated with annual healthcare expenditures of $20 billion and significant costs in lost work productivity and health-related quality-of-life.

    Although not uncommon, there is still much that is unknown about IBS-C, and its diagnosis has largely remained dependent on symptom-based criteria with their share of limitations.

    This activity has been designed to update HCPs’ knowledge of IBS-C and to improve their competence and performance in treating it.

    Target Audience:

    The following HCPs: Gastroenterologists and primary care physicians; physician assistants, nurse practitioners, and pharmacists who practice in gastroenterology; and any other HCPs with an interest in or who clinically encounter patients with IBS-C.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1
    • CME credits awarded by: ScientiaCME
    • Material last updated: August 18, 2021
    • Expiration of CME credit: August 18, 2023
  • FREE

    Practice updates in treating advanced-stage gastric and gastroesophageal junction cancers

    Activity Description / Statement of Need:
    In this online, self-learning activity:

    Gastric cancer (GC) accounts for over 26,000 new cases and 11,000 related deaths in the U.S. annually, and while malignancies of the esophagus and gastroesophageal junction (GEJC) are associated with 19,000 and 15,000, respectively. GEJ tumors clinically more often resemble gastric than esophageal cancers, and GEJ cancers are often included in studies of GC. Adenocarcinomas represent more than 95% of gastric cancers and around 75% of esophageal cancers in the US. Systemic therapy is the mainstay of treatment for advanced and metastatic disease. There is a widening number of treatment options for GC and GEJC with approved and investigational agents. This learning activity has therefore been designed to bring HCPs’ knowledge of the rationale behind treatment of GC and GEJC up to date and to enhance their competence and performance in the management of it.

    Target Audience:
    HCPs including: Medical oncologists, pathologists, physician assistants, nurse practitioners, and pharmacists specializing in oncology; and any other clinicians involved or interested in the treatment of GC & GEJC.

    See full details chevron_right
    • Cost: Free
    • Credit hours: 1.25
    • CME credits awarded by: ScientiaCME
    • Format: On-Demand Online
    • Material last updated: 10/31/2021
    • Expiration of CME credit: 10/31/2022